Equities

Predictive Oncology Inc

POAI:NAQ

Predictive Oncology Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.8163
  • Today's Change-0.064 / -7.25%
  • Shares traded251.97k
  • 1 Year change-74.25%
  • Beta1.1374
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Predictive Oncology Inc share price to rise to 3.00 in the next year from the last price of 0.8163.
High267.5%3.00
Med267.5%3.00
Low267.5%3.00

Earnings history & estimates in USD

On May 12, 2022, losses of -1.00 per share.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate-1.60%
Predictive Oncology Inc reported annual 2021 losses of -7.20 per share on Mar 31, 2022.
Average growth rate+83.71%
More ▼

Revenue history & estimates in USD

of 363.00k.
Average growth rate-3.39%
Predictive Oncology Inc. had revenues for the full year 2022 of 1.51m. This was 5.99% above the prior year's results.
Average growth rate+9.70%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.